ArticleFrontiers in oncology2026
Imaging features and differentiation between benign and malignant Brenner tumors in a multi-center cohort.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the imaging features of histopathologically confirmed ovarian Brenner tumors (BTs) and to improve the accuracy of differential diagnosis between benign and borderline or malignant variants. Methods: A retrospective analysis was conducted on clinical and imaging data from patients with pathologically confirmed ovarian BTs, collected from five medical centers between January 2014 and December 2024. Univariate and multivariate logistic regression analyses were utilized to identify independent risk factors associated with borderline or malignant BTs. Results: Clinically, the incidence of elevated serum CA125 levels was significantly greater in the borderline/malignant group compared to the benign group (p < 0.05). Regarding imaging characteristics, variables including maximum tumor diameter, tumor composition, tumor margin, presence of papillary projections, calcification pattern, degree of enhancement, as well as CT attenuation values between the non-contrast and the arterial or venous phases, demonstrated statistically significant differences between benign and malignant tumors (p < 0.05). Tumor maximum diameter, papillary projections and venous-phase CT net enhancement were identified as independent risk factors associated with borderline/malignant BTs. The combined model showed promising discriminative ability (AUC 0.956), but this result requires extreme caution. Conclusion: In pathology-confirmed BTs, maximum tumor diameter, presence of papillary projections, and venous-phase CT net enhancement are valuable markers for differentiating benign from borderline or malignant subtypes. These features may assist in preoperative imaging assessment and risk categorization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.